Biohaven Pharmaceutical is partnering with reality TV star Khloe Kardashian to promote a migraine medication in Biopharma.
Biohaven pharmaceutical ( BHVN) – “Get Report” has teamed up with reality TV star Khloe Kardashian to promote Biopharma’s nurtec ODT migraine medication, the company said.
Shares of the New Haven, Conn., company were up 4.6% at $ 76.23 At the last check.
Sales of the pill, generally known as rimegepant, totaled $ 1.2 million in the first quarter after the drug received approval from the food and drug Administration in February.
In may, Biohaven said that in the first full six weeks after the launch of Nurtec, ODT showed the largest increase compared to the previous week in the treatment of new acute migraines.
To date, more than 6,000 medical professionals have written more than 6,000 prescriptions.
Bloomberg reported that Nurtec resorption generates revenue this year of about $ 50 million and will exceed $ 1 billion by 2024, citing average analyst estimates.
Biohaven said Nurtec resorption quickly relieves pain, returns patients to normal work within one hour and for many patients lasts up to 48 hours.
According to Biohaven, the world health organization classifies migraines as one of the 10 most disabling diseases. Migraines are characterized by debilitating attacks lasting from four to 72 hours with multiple symptoms.
The company said that 90% of migraine sufferers are unable to work or function normally during an attack.
Kardashian, who suffers from migraines, said in a statement that Nurtec resorption “worked quickly and allowed me to get back to normal so I could get back to my day.”
The reality star has been criticized for her past associations with certain weight loss products.
Biohaven faces competition in the field of migraine treatment from companies such as Amgen ( amgn ) – get a report , H. Lundbeck A / S, hluyy El Eli Lilly ( lly) – get a report .